The National Institutes of Health (NIH) has granted $718,136 in funding to the University of California San Francisco (UCSF) to discover and optimise oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals.

Anacor has partnered with UCSF to develop new antimalarial agents.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition Anacor works with Medicines for Malaria Venture (MMV) to develop AN3661, a boron-based antimalarial compound currently in preclinical trials.

Anacor and MMV plan to conduct Phase 1 and Phase 2 proof of concept studies for AN3661, where GSK will have the option to license the programme.

 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.